title: Phorbol 12-myristate 13-acetate induces protein kinase ceta-specific proliferative response in astrocytic tumor cells.
abstract: Protein kinase C (PKC) activation has been implicated in cellular proliferation in neoplastic astrocytes. The roles for specific PKC isozymes in regulating this glial response, however, are not well understood. The aim of this study was to characterize the expression of PKC isozymes and the role of PKC-eta expression in regulating cellular proliferation in two well characterized astrocytic tumor cell lines (U-1242 MG and U-251 MG) with different properties of growth in cell culture. Both cell lines expressed an array of conventional (alpha, betaI, betaII, and gamma) and novel (theta and epsilon) PKC isozymes that can be activated by phorbol myristate acetate (PMA). Another novel PKC isozyme, PKC-eta, was only expressed by U-251 MG cells. In contrast, PKC-delta was readily detected in U-1242 MG cells but was present only at low levels in U-251 MG cells. PMA (100 nm) treatment for 24 h increased cell proliferation by over 2-fold in the U-251 MG cells, whereas it decreased the mitogenic response in the U-1242 MG cells by over 90%. When PKC-eta was stably transfected into U-1242 MG cells, PMA increased cell proliferation by 2.2-fold, similar to the response of U-251 MG cells. The cell proliferation induced by PMA in both the U-251 MG and U-1242-PKC-eta cells was blocked by the PKC inhibitor bisindolylmaleimide (0.5 micrometer) and the MEK inhibitor, PD 98059 (50 micrometer). Transient transfection of wild type U-251 with PKC-eta antisense oligonucleotide (1 micrometer) also blocked the PMA-induced increase in [(3)H]thymidine incorporation. The data demonstrate that two glioblastoma lines, with functionally distinct proliferative responses to PMA, express different novel PKC isozymes and that the differential expression of PKC-eta plays a determining role in the different proliferative capacity.
authors.affiliation: Departments of Pathology (Neuropathology), Biomedical Engineering, and Pharmacology, University of Virginia, Charlottesville, Virginia 22908, USA. imh5c@virginia.edu
authors.forename: I M
authors.initials: IM
authors.lastname: Hussaini
authors.forename: L R
authors.initials: LR
authors.lastname: Karns
authors.forename: G
authors.initials: G
authors.lastname: Vinton
authors.forename: J E
authors.initials: JE
authors.lastname: Carpenter
authors.forename: G T
authors.initials: GT
authors.lastname: Redpath
authors.forename: J J
authors.initials: JJ
authors.lastname: Sando
authors.forename: S R
authors.initials: SR
authors.lastname: VandenBerg
mesh_terms: D001253:Astrocytes / Q000378:metabolism* / Q000473:pathology*; D002273:Carcinogens / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism*; D011493:Protein Kinase C / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D002273:Carcinogens; D007527:Isoenzymes; C081975:protein kinase C eta; D011493:Protein Kinase C; D013755:Tetradecanoylphorbol Acetate